Home
About
Overview
Sharing Data
ORCID
Help
History (1)
A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. Gynecol Oncol. 2007 Sep; 106(3):596-603.
View in:
PubMed
subject areas
Adult
Adult
Aged
Aged
Angiogenesis Inhibitors
Angiogenesis Inhibitors
Antigens, CD
Antigens, CD
Biomarkers, Tumor
Biomarkers, Tumor
Dose-Response Relationship, Drug
Dose-Response Relationship, Drug
Endothelial Protein C Receptor
Endothelial Protein C Receptor
Female
Female
Fibroblast Growth Factor 2
Fibroblast Growth Factor 2
Humans
Humans
Leiomyosarcoma
Leiomyosarcoma
Middle Aged
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Recurrence, Local
Neovascularization, Pathologic
Neovascularization, Pathologic
Proportional Hazards Models
Proportional Hazards Models
Receptors, Cell Surface
Receptors, Cell Surface
Thalidomide
Thalidomide
Uterine Neoplasms
Uterine Neoplasms
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor A
authors with profiles
Doris M Benbrook